What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally

1 week ago 6

Jonathan Ponciano, The Motley Fool

Sun, January 11, 2026 astatine 12:03 PM CST 5 min read

The main aesculapian serviceman astatine Apogee Therapeutics sold 18,700 shares of the biotech for astir $1.46 million.
This merchantability represented 8.09% of Dambkowski’s nonstop holdings, reducing his nonstop stake, arsenic reported, from 231,223 to 212,523 shares.
The transaction was wholly direct, with nary shares attributed to trusts oregon indirect entities, and progressive the workout of 14,025 options instantly anterior to the sale.
These 10 stocks could mint the adjacent question of millionaires ›

Carl Dambkowski, the main aesculapian serviceman astatine Apogee Therapeutics (NASDAQ:APGE), executed an open-market merchantability of 18,700 shares connected Wednesday pursuing the workout of 14,025 banal options, for a full transaction worth of $1.46 million, according to an SEC Form 4 filing.

Metric

Value

Shares sold (direct)	18,700
Transaction value	$1.5 million
Post-transaction shares (direct)	212,523
Post-transaction worth (direct ownership)	$16.8 million

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($77.84); post-transaction worth based connected Wednesday's marketplace close.

How does the size of this merchantability comparison to Dambkowski’s erstwhile merchantability transactions?
This disposition of 18,700 shares is substantially larger than the caller median merchantability size of 3,690 shares for Dambkowski, and besides exceeds the median merchantability size of 6,665 shares observed successful earlier periods, highlighting the interaction of the enactment workout connected transaction scale.
What was the operation and timing of the transaction successful narration to enactment exercises?
The transaction progressive exercising 14,025 options for communal banal and instantly selling 18,700 shares.
What is Dambkowski’s remaining equity vulnerability aft this transaction?
Dambkowski retains 212,523 straight held shares, valued astatine astir $16.8 cardinal arsenic of Wednesday.
Was the transaction terms aligned with prevailing marketplace levels?
The weighted mean merchantability terms was astir $77.84 per share, intimately matching the Wednesday marketplace adjacent of $78.95, reflecting execution adjacent the prevailing terms level connected that date.

Metric

Value

Market capitalization	$5.3 billion
Net income (TTM)	($253.67 million)
1-year terms change	60%

Apogee Therapeutics develops biologic therapies targeting atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications.
The institution operates a biotechnology R&D model, generating worth done objective advancement of proprietary biologics with a absorption connected extended half-life antibody platforms.
It targets patients with chronic inflammatory diseases, with superior customers expected to beryllium healthcare providers, hospitals, and specialty clinics treating atopic dermatitis and COPD.